DK148479B - Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid - Google Patents
Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid Download PDFInfo
- Publication number
- DK148479B DK148479B DK219876AA DK219876A DK148479B DK 148479 B DK148479 B DK 148479B DK 219876A A DK219876A A DK 219876AA DK 219876 A DK219876 A DK 219876A DK 148479 B DK148479 B DK 148479B
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- formula
- compound
- dioxide
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 15
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 33
- -1 5-methyl-3-isoxazolylcarbamoyl Chemical group 0.000 claims description 22
- FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 claims description 5
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 5
- 229940081974 saccharin Drugs 0.000 claims description 3
- 235000019204 saccharin Nutrition 0.000 claims description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 229910052717 sulfur Inorganic materials 0.000 description 14
- 239000002585 base Substances 0.000 description 9
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 239000012442 inert solvent Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- OCEZJTJAJHRHDA-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound O1C(C)=CC(NC(=O)CN2S(C3=CC=CC=C3C2=O)(=O)=O)=N1 OCEZJTJAJHRHDA-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000020477 pH reduction Effects 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- DXJICGSIRAJIDN-UHFFFAOYSA-N 2-chloro-N-(5-methyl-3-isoxazolyl)acetamide Chemical compound CC1=CC(NC(=O)CCl)=NO1 DXJICGSIRAJIDN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CPIFFCMMBZLKDK-UHFFFAOYSA-N 2-methyl-1,1-dioxo-3h-1$l^{6},2-benzothiazin-4-one Chemical compound C1=CC=C2S(=O)(=O)N(C)CC(=O)C2=C1 CPIFFCMMBZLKDK-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- CEFGWFXVHFZNQW-UHFFFAOYSA-N 4-hydroxy-n-(1,2-oxazol-3-yl)-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxamide Chemical class N1S(=O)(=O)C2=CC=CC=C2C(O)=C1C(=O)NC=1C=CON=1 CEFGWFXVHFZNQW-UHFFFAOYSA-N 0.000 description 1
- JQVPAYCOPULQCA-UHFFFAOYSA-N 5-methyl-3h-1,2-oxazol-2-amine Chemical compound CC1=CCN(N)O1 JQVPAYCOPULQCA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- KNYFJYVFUYERQR-UHFFFAOYSA-N methyl 2-(3-oxo-1,2-benzothiazol-2-yl)acetate Chemical compound C1=CC=C2C(=O)N(CC(=O)OC)SC2=C1 KNYFJYVFUYERQR-UHFFFAOYSA-N 0.000 description 1
- GEUURTZIEGFZAG-UHFFFAOYSA-N methyl 4-hydroxy-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxylate Chemical compound C1=CC=C2S(=O)(=O)NC(C(=O)OC)=C(O)C2=C1 GEUURTZIEGFZAG-UHFFFAOYSA-N 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005730 ring rearrangement reaction Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
O
148479 i
Den foreliggende opfindelse angår en særegen fremgangsmåde til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxa-zolylcarbamoyl)-2-methyl-2H-l,2-benzothiazin-l,l-dioxid, der er en kendt forbindelse med nyttig antiinflammatorisk virk-5 ning, og som er et vigtigt kommercielt middel kaldet isoxicam (NFN navn).
Fra beskrivelsen til USA patent nr. 3.822.258 er det kendt, at forskellige 4-hydroxy-3-(3-isoxazolylcarbamoyl)--2H-l,2-benzothiazin-l,l-dioxider, som også har anti-inflam-10 matorisk virkning, kan fremstilles ved omsætning af et f.eks.
2-methylsubstitueret-4-hydroxy-2H-l,2-benzothiazin-3-carboxy-lat-l,l-dioxid med en f.eks. 5-methylsubstitueret 3-aminois-oxazol.
Andre fremgangsmåder til fremstilling af 4-hydroxy-3-15 -(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-l,2-benzothia- zin-1,1-dioxid er beskrevet i USA patentskrift nr. 3.853.862, hvor et vigtigt mellemprodukt er N-aryl-N'-alkyl-N'-(2'-alk-oxycarbamoyl-benzensulfonyl)-glycinamid.
Ifølge USA patentskrift nr. 3.821.211 omsættes en pyr-20 rolidinenamin af 3,4-dihydro-2-methyl-4-oxo-2H-l,2-benzothia-zin-1,1-dioxid med phosgen og triethylamin, hvorefter den dannede forbindelse omsættes med 3-amino-5-methylisoxazol, hvorpå der hydrolyseres.
Beslægtede forbindelser med antiinflammatorisk virkning 25 og fremgangsmåder til fremstilling deraf er beskrevet i USA patentskrift nr. 2.591.584 og nr. 3.501.466.
Endvidere er det kendt at fremstille 3-methoxycarbo-nyl-4-hydroxy-2H-l,2-benzothiazin-l,l-dioxid ud fra 3-oxo-l,2--benzisothiazolin-2-eddikesyremethylester, jfr. Lombardino et 30 al., J. Med. Chem. 14, 1171-1175 (1971).
En lignende reaktion, hvor der gås ud fra den analoge methylketon, er beskrevet i Zinnes et al., J. Org. Chem. 30, 2241-2246 (1965).
Omlejringsreaktioner med substituerede isoxazoler og 35 oxadiazoler er generelt beskrevet af H.C. Van der Pias, Ring 2 148479 o
Transformations of Heterocycles, bind 1, kapitel 3, 1973,
Academic Press, London, New York.
Ved fremgangsmåden ifølge opfindelsen fremstilles 4-hy-droxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-l,2-benz-5 oxthiazin-1,1-dioxid med formlen
Sk 1 C i CN§ (1) i II ^-7
10 OH 0 |l I
v A
^CH3 og fremgangsmåden er ejendommelig ved, at a) 3-amino-5-methylisoxazol med formlen 15 CH, Υχ ^-νη2 20 omsættes med et halogenacetylhalogenid til dannelse af en forbindelse med formlen % Yx |_I 0 (III) 25 'v^NH-C-CH2-halogen b) en forbindelse med formlen III omsættes med et salt af saccharin til dannelse af en forbindelse med formlen
o .O
30 / \ .ch9 li lY\? «V)
C_NH
s Xi jl N Ul 35 ^CH3
O
3 148479 c) en forbindelse med formlen IV under dobbelt omlejring omsættes med et alkalimetalalkoxid af en lavere alkohol, fortrinsvis natriummethoxid, i et indifferent opløsningsmiddel, fortrinsvis dimethylformamid, ved en temperatur fra ca.
5 60 til ca. 70°C efterfulgt af syrning til dannelse af forbin delsen med formlen
V
Vnh (v) 10 0.
OH N 1) CHjCCHj d) en forbindelse med formlen V methyleres ved omsæt-15 ning ved en temperatur fra ca. 10 til ca. 25°C med et methy- leringsmiddel i et vandigt indifferent opløsningsmiddel indeholdende overskud af base efterfulgt af syrning til dannelse af forbindelsen med formlen 0. ,0 20 /CH3 (VI)
x I i 0V
T li li ° OH N_U-CH-CCH, 25 ©g * 0 e) en forbindelse med formlen VI under ringomlejring til gendannelse af isoxazolylringen opvarmes til ca. 100°C med en,fortrinsvis organisk, base, navnlig triethylamin, i et indifferent opløsningsmiddel, fortrinsvis xylen, til dannel- 30 se af forbindelsen med formlen I.
Fremgangsmåden ifølge opfindelsen udgør en effektiv metode til ud fra det let tilgængelige og billige udgangsmateriale natriumsaccharin at lave det ønskede aktive slutprodukt med formlen I, der hidtil har været ret kostbart at 35 fremstille ved ovennævnte kendte metoder på grund af udgangs- 148479
O
4 materialernes og syntesevejenes natur.
Nedenstående definitioner gælder for alle de her omhandlede forbindelser og reaktionsprocedurer samt for reagenser og intermediære anvendt til fremstilling deraf. "Ha-5 logen" indbefatter chlor, brom og iod, "alkalimetal" indbefatter natrium og kalium, ved udtrykket "lavere alkohol" forstås ligekædede eller forgrenede alkoholer med 1-5 car-bonatomer. Ved "baser" skal forstås sådanne, der sædvanligvis anvendes i vandige reaktionsmedier, såsom natriumhy-10 droxid og kaliumhydroxid. Ved en "organisk base" forstås sådanne baser, der sædvanligvis anvendes i vandfri reaktionsmedier, såsom pyridin, diethylamin og triethylamin. "Metalhydridbaser" indbefatter alkalimetal- og jordalkali-metalhydrider såsom natriumhydrid, kaliumhydrid og calci-1s umhydrid.
I overensstemmelse med den foreliggende opfindelse startes fremstillingen af 4-hydroxy-3-(5-methyl-3-isoxazo-lylcarbamoyl)-2-methyl-2H-l,2-benzothiazin-l,l-dioxid ud fra 3-amino-5-methylisoxazol med formlen II, der omsættes med et 20 halogenacetylhalogenid såsom chloracetylchlorid f.eks. i et indifferent opløsningsmiddel, såsom chloroform, især indeholdende overskud af organisk base, fortrinsvis pyridin. Efter omrøring af reaktionsblandingen i flere timer fås forbindelsen med formlen III, dvs. 3-(halogenacetamido)-5-methylisoxa-25 zol som derpå kondenseres med et alkalimetalsalt af saccharin, fortrinsvis natriumsaccharin (der er det billigste) i et indifferent opløsningsmiddel såsom N,N'-dimethylformamid (DMF). Reaktanterne anvendes i omtrentlig ækvimolære mængder, og kondensationsreaktionen kan gennemføres ved f.eks. ca. 100°C 30 i ca. 3 timer til dannelse af forbindelsen med formlen IV, dvs. 2,3-dihydro-N-(5-methyl-3-isoxazolyl)-3-oxo-l,2-benziso-thiazol-2-acetamid-l,l-dioxid, som i trin c) underkastes dobbelt omlejring. Dette gennemføres under anvendelse af et al-kalimetalalkoxid af en lavere alkohol, fortrinsvis natrium-35 methoxid, i et indifferent opløsningsmiddel ved reguleret tem-
O
5 148479 peratur. Sædvanligvis anvendes mere end 3 mol, fortrinsvis ca. 4 mol natriummethoxid pr. mol forbindelse med formlen IV i dimethylformamid, idet temperaturen holdes fra ca.
60°C til ca. 70°C ved omlejringen, hvorefter der syrnes f.eks.
5 med en mineralsyre såsom saltsyre, hvorved fås forbindelsen med formlen V, dvs. 1-{[5-(4-hydroxy-2H-1,2-benzothiazin-3-yl)--l,2,4-oxadiazol-3-yl]methyl}ethanon-S,S-dioxid. Det gunstige resultat af denne dobbeltomlejring afhænger af reaktionstemperaturen, da lavere eller højere temperaturer har vist sig at 10 give utilfredsstillende resultater.
Omdannelsen af forbindelsen V til forbindelsen VI gennemføres under anvendelse af i og for sig kendt methylerings-teknik under anvendelse af standardmethyleringsmidler, såsom methyliodid og/eller dimethylsulfat, i et vandigt indifferent 15 opløsningsmiddel, såsom en lavere alkohol/vandblanding, indeholdende overskud af base. Reaktionstemperaturen reguleres mellem ca. 10 og ca. 25°C, da højere temperaturer ikke fører til den ønskede forbindelse med formlen VI, hvilket forklares nærmere i det følgende. Sædvanligvis anvendes overskud, for-2o trinsvis to ækvivalenter vandig natriumhydroxid med det under navnet "Solvent No. Ill" (SOLOX) forhandlede opløsningsmiddel med et overskud, fortrinsvis 1,5 ækvivalenter dimethylsulfat.
SOLOX forhandles af U.S. Industriel Chemical Co., New York, N.Y. og er en generelt anvendelig opløsningsmiddelblanding 25 indeholdende specielt denatureret alkohol med lavt indhold af opløsningsmodificerende stoffer. Ved omrøring af ovennævnte reaktionsblanding i ca. 3 timer ved en temperatur mellem ca.
10°C og ca. 25°C fås efter syrning med en mineralsyre forbindelsen med formlen VI, dvs. 1- {[5-(4-hydroxy-2-methyl-2H-l,2-30 -benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}ethanon-S,S--dioxid.
Overføringen af forbindelsen med formlen VI til den tilsigtede forbindelse med formlen I gennemføres ved opvarmning til ca. 100°C i et indifferent opløsningsmiddel, fortrinsvis 35 xylen, indeholdende en organisk base såsom triethylamin. For-
O
6 148479 bindeisen (IV) kan dog også underkastes opvarmning til 90-100°C i en vandig base såsom natriumhydroxid, og derpå fås ligeledes forbindelsen I, men først efter syrning.
De tilsvarende alkalimetalsalte, jordalkalimetalsal-5 te og aminsalte af forbindelsen med formlen (I) kan fremstilles ved at behandle forbindelsen med formlen (I) med den ønskede base, f.eks. natriumalkoxid, kaliumalkoxid, natriumhydroxid, kaliumhydroxid, calciumhydroxid, pyrrolidin og lignende på i og for sig kendt måde. Eventuelt kan det ønskede 10 alkalimetalsalt af forbindelsen (I) fås direkte ved under trin e) ved fremgangsmåden ifølge opfindelsen at udelade syrningsreaktionen til sidst, hvis dette gennemføres med stærk vandig base.
Det ved fremgangsmåden ifølge opfindelsen anvendte 15 udgangsmateriale, 2-amino-5-methylisoxazol med formlen (II) er kendt og kan fremstilles som beskrevet i beskrivelsen til hollandsk patent nr. 6.511.924 og er i øvrigt kommercielt tilgængelig fra firmaet Hoffmann La Roche, Nutley, New Jersey.
20 Forbindelsen med formlen (I), der fremstilles ved fremgangsmåden ifølge opfindelsen er kendt, f.eks. fra beskrivelsen til USA patent nr. -3.816.628, som antiinflammato-risk, antipyretisk og analgetisk aktiv. Ved oral indgift til rotter i en dosis på 10-200.mg/kg kan den bevirke for-25 mindskelse af potehævning fremkaldt ved injektion i trædepuderne med et irriterende stof såsom carrageenin. Ved oral, terapeutisk eller profylaktisk indgift i en mængde på 15-200 mg/kg inhiberer forbindelsen I polyarthritis hos rotter induceret med et hjælpestof. Orale doser på 25-100 mg/kg 30 er tilstrækkelig til at inhibere gærinduceret hypertermi hos rotter. Ved orale doser på 25-200 mg/kg udviser stoffet en signifikant analgetisk virkning bestemt ved phenylquinonvrid-ningstesten på mus.
Generelt vil forbindelsen med formlen I indiceres ved 35 tilstande såsom smerter fremkaldt af arthritis, bursitis og
O
7 148479 lignende. En daglig dosis på ca. 0,5 g til ca. 2 g opdelt i flere doser anbefales til pattedyr med en legemsvægt på ca. 70 kg til at lindre smerten og hævningen forbundet med disse tilstande og kan indgives enten oralt eller ved in-5 jektion.
Fremgangsmåden ifølge opfindelsen forklares nærmere i de følgende eksempler.
Eksempel 1 10 Trin a) OH, O.
T (III) L_i s ^NH-C-CH2C1 15 3-(Chloracetamido)-5-methylisoxazol
Til 800 ml chloroform sættes 118 g (1,12 mol) 3-ami-no-5-methylisoxazol efterfulgt af 118 g (1,5 mol) pyridin.
Til denne opløsning sættes 147 g (1,3 mol) chloracetylchlo-20 rid, idet temperaturen holdes på 0-10°C. Reaktionsblandingen omrøres derefter ved stuetemperatur i 1 time, filtreres og tørres i en vakuumekssikkator, hvorved fås 116 g (56%) 3-(chloracetamido)-5-methylisoxazol med smp. 192-195°C. Dette materiale har en let irriterende virkning på huden og 25 skal derfor omgås med behørig forsigtighed.
Analyse for 0^1^01^02 (174,58): C% H% N% Cl%
Beregnet 41,28 4,04 16,05 20,31
Fundet 41,55 4,10 15,79 20,50.
Eksempel 2
Trin Ta) ο δ 148479 CL /.0 5 \ /ch2\° |J^n/ ^C-HH _ (IV)
" J I
0 10 2,3-Dihydro-N-(5-methyl-3-isoxazolyl)-3-oxo-l,2-benzisothia- zol-2-acetamld-l, l-dioxid (IV)__
Til 2,31 liter DMF sættes 479 g (2,75 mol) 3-(chlor-acetamido)-5-methylisoxazol og derpå 699 g (2,9 mol) natrium-saccharin-dihydrat. Blandingen opvarmes til 100°C, og denne 15 temperatur holdes i 2 timer. Den afkølede reaktionsblanding hældes i 9 liter vand, filtreres, og den våde filterkage omkrystalliseres af 15 liter ethanol, hvorved fås 658 g (74,8%) 2,3-dihydro-N-(5-methyl-3-isoxazolyl)-3-cxo-l,2-benz-isothiazol-2-acetamid-l,l-dioxid med smp. 218-220°C. IR- og 20 NMR-spektrene stemmer overens med strukturen.
Analyse for C^H^N-jO^S (321,30) : C% H% N% S%
Beregnet 48,60 3,45 13,08 9,98
Fundet 48,62 3,61 13,28 10,19.
Eksempel 3
Trin c) o 148479 9 Λν r^5 Xnh
III
kkkA /ov (v> OH i f ? N-ϋ-CH2CCH3 10 1-^[5-(4-Hydroxy-2H-l,2-benzothiazin-3-yl)-1,2,4-oxadiazol- -3-yl3methyjr ethanon-S,S-dioxid (V)_
Til 300 ml DMF sættes 67,5 g (1,25 mol) natriummeth-oxid. Blandingen opvarmes til 55°C, hvorefter der tilsættes en opløsning af 100 g (0,31 mol) 2,3-dihydro-N-(5-methyl-3-15 -isoxazolyl)-3-oxo-l,2-benzisothiazol-2-acetamid-l,l-dioxid i 350 ml DMF. Temperaturen holdes på 60-70°C i 1/2 time, hvorefter blandingen hældes i vandig syre. Der fås 71 g (71%) råprodukt med formlen (V).
Stoffet renses ved behandling med varm vandig metha-20 nol, hvorved fås l-{[5—(4-hydroxy-2H-l,2-benzothiazin-3-yl)--1,2,4-oxadiazol-3-yl]methyl} ethanon-S,S-dioxid med smp-187-189°C. IH- og NMR-spektrene stemmer overens med strukturen.
Analyse for cy3HnN3®5S (321,30) : 25 C% H% N% S%
Beregnet 48,60 3,45 13,08 9,98
Fundet 48,55 3,49 12,93 10,16.
o
Eksempel 4
Trin d) 10 148479 %S^° ch3 <^S /°\ (VI) 0h J I " N--!1-CH2CCH3 10 l-{[5-(4-Hydroxy-2-meth.yl-2H-l,2-benzothiazin-3-yl)-1,2,4- -oxadiazol-3-yl]-methyl) ethanon-S,S-dioxfd (VI)_ ~ ~ ~
Til 160 ml 56%'s vandig "Solvent No. 3" (S0L0X) sættes 3,21 g (0,01 mol) l-*[[5-(4-hydroxy-2H“l,2-benzothiazin--3-yl)-l,2,4-oxadiazol-3-yl]-methylJethanon-S,S-dioxid, og 15 blandingen afkøles til 5°C, hvorefter der dråbevis tilsættes 20 ml 1 N natriumhydroxidopløsning, idet temperaturen holdes under 10°C. Til denne blanding sættes 1,8 g (0,015 mol) di-methylsulfat, og reaktionsblandingen omrøres i 3 timer med en maksimaltemperatur på 25°C. Derpå syrnes med 6 N saltsyre, 20 hvorved fås 2,8 g (85%) analytisk rent 1-{(5-(4-hydroxy-2-methyl -2H-1,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methylj ethanon-S,S-dioxid med smp. 143-145°C. IR- og NMR-spektrene er i overensstemmelse med strukturen.
Analyse for C-^H^gN^O^S (335 ? 32) : 25 C%- H% N% S%
Beregnet 50,15 3,91 12,53 9,56
Fundet 49,97 3,98 12,52 9,72.
o 148479 11
Eksempel 5 Trin e)
-- O O
5 I
(i) OH O \- li
A
O^CHj 10 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-l,2- -benzothiazin-l,l-dioxid (I)_
Til 80 ml xylen sættes 4,0 g (0,012 mol) 1-1[5-(4-hy-droxy-2-methyl-2H-l,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]-15 methyl}ethanon-S,S-dioxid og derpå 0,4 g (0,0046 mol) triethyl-amin, og temperaturen indstilles på 115-120°C i 30 minutter. Reaktionsblandingen afkøles og filtreres, hvorved fås 3,6 g (90%) 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl--2H-1,2-benzothiazin-l,1-dioxid med smp. 252-254°C.
20 Analyse for cy4Hi3N3^5® (335,32): C% H% N% S%
Beregnet 50,15 3,91 12,53 9,56
Fundet 49,96 3,95 12,47 9,58.
Claims (1)
148479 O Patentkrav. Fremgangsmåde til fremstilling af 4-hydroxy-3-(5-methyl- 3-isoxazolylcarbamoyl)-2-methyl-2H-l,2-benzothiazin-l,1-5 -dioxid med formlen . ^ch3 ίο I " \ L 'Vi N kendetegnet ved, at 15 a) 3-amino-5-methylisoxazol med formlen CH, V°x- Li ^NH, 20 i omsættes med et halogenacetylhalogenid til dannelse af en forbindelse med formlen CH, "V/N, - T il o NH-C-C^-halogen b) en forbindelse med formlen III omsættes med et salt af saccharin til dannelse af en forbindelse med form-30 len d5x - 35. li f N 1 \0^^CH3
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57756875 | 1975-05-21 | ||
US05/577,568 US3957772A (en) | 1975-05-21 | 1975-05-21 | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide |
Publications (3)
Publication Number | Publication Date |
---|---|
DK219876A DK219876A (da) | 1976-11-22 |
DK148479B true DK148479B (da) | 1985-07-15 |
DK148479C DK148479C (da) | 1985-12-16 |
Family
ID=24309281
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK219876A DK148479C (da) | 1975-05-21 | 1976-05-19 | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
DK25280A DK148478C (da) | 1975-05-21 | 1980-01-22 | 4-hydroxy-2h-1,2-benzothiazin-s,s-dioxidderivater til brug som mellemprodukter ved fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzo-thiazin-1,1-dioxid |
DK25180A DK149752C (da) | 1975-05-21 | 1980-01-22 | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK25280A DK148478C (da) | 1975-05-21 | 1980-01-22 | 4-hydroxy-2h-1,2-benzothiazin-s,s-dioxidderivater til brug som mellemprodukter ved fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzo-thiazin-1,1-dioxid |
DK25180A DK149752C (da) | 1975-05-21 | 1980-01-22 | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid |
Country Status (10)
Country | Link |
---|---|
CH (1) | CH629802A5 (da) |
DK (3) | DK148479C (da) |
ES (1) | ES448088A1 (da) |
FI (1) | FI63230C (da) |
IE (1) | IE43102B1 (da) |
IN (1) | IN143577B (da) |
MX (1) | MX3139E (da) |
NO (1) | NO145917C (da) |
PH (2) | PH14848A (da) |
SE (2) | SE429043B (da) |
-
1976
- 1976-03-30 IN IN548/CAL/76A patent/IN143577B/en unknown
- 1976-05-04 IE IE947/76A patent/IE43102B1/en unknown
- 1976-05-10 MX MX000219U patent/MX3139E/es unknown
- 1976-05-17 PH PH18443A patent/PH14848A/en unknown
- 1976-05-19 DK DK219876A patent/DK148479C/da active
- 1976-05-20 SE SE7605752A patent/SE429043B/xx not_active IP Right Cessation
- 1976-05-20 NO NO761724A patent/NO145917C/no unknown
- 1976-05-20 ES ES448088A patent/ES448088A1/es not_active Expired
- 1976-05-20 FI FI761431A patent/FI63230C/fi not_active IP Right Cessation
- 1976-05-21 CH CH642776A patent/CH629802A5/de not_active IP Right Cessation
-
1980
- 1980-01-22 DK DK25280A patent/DK148478C/da active
- 1980-01-22 DK DK25180A patent/DK149752C/da not_active IP Right Cessation
- 1980-03-03 SE SE8001649A patent/SE447112B/sv not_active IP Right Cessation
-
1981
- 1981-01-28 PH PH25141A patent/PH16804A/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK25280A (da) | 1980-01-22 |
DK25180A (da) | 1980-01-22 |
IE43102B1 (en) | 1980-12-17 |
SE429043B (sv) | 1983-08-08 |
SE7605752L (sv) | 1976-11-22 |
CH629802A5 (en) | 1982-05-14 |
ES448088A1 (es) | 1977-07-01 |
DK219876A (da) | 1976-11-22 |
SE8001649L (sv) | 1980-03-03 |
FI63230B (fi) | 1983-01-31 |
NO145917C (no) | 1982-06-23 |
MX3139E (es) | 1980-05-06 |
DK149752C (da) | 1987-03-16 |
NO761724L (da) | 1976-11-23 |
FI761431A (da) | 1976-11-22 |
DK148479C (da) | 1985-12-16 |
DK148478B (da) | 1985-07-15 |
DK149752B (da) | 1986-09-22 |
IE43102L (en) | 1976-11-21 |
FI63230C (fi) | 1983-05-10 |
NO145917B (no) | 1982-03-15 |
DK148478C (da) | 1985-12-16 |
PH14848A (en) | 1982-01-06 |
SE447112B (sv) | 1986-10-27 |
IN143577B (da) | 1977-12-31 |
PH16804A (en) | 1984-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS202515B2 (en) | Method of producing novel 4-hydroxy-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides | |
BROWN et al. | Structure and antimicrobial activity of the 3-aminorhodanines | |
JPH04221368A (ja) | 抗炎症剤としての3,5−ジ−tert−ブチル−4−ヒドロキシフェニルチアゾリル、オキサゾリルおよびイミダゾリルメタノン並びに類似化合物 | |
JPS6340430B2 (da) | ||
US4022796A (en) | 2,3-Dihydro-N-(5-methyl-3-isoxazolyl)-3-oxo-1,2-benzothiazole-2-acetamide 1,1-dioxide | |
KR900004126B1 (ko) | 아릴피페라지닐-에틸(또는 부틸)-페닐-헤테로시클릭 화합물 | |
US4076722A (en) | Composition containing alkyl 2-{[({[(5-methyl-3-isoxazolyl)-amino]carbonyl}methyl)amino]sulfonyl}benzoate and an alkali metal alkoxide of a lower alcohol in an inert solvent | |
EP0259085B1 (en) | 2-guanidino-4-arylthiazoles for treatment of peptic ulcers | |
JPS58128384A (ja) | ベンゾジオキシン化合物、その製造方法、および精神作用障害治療用医薬組成物 | |
EP0592664A1 (en) | Novel diphenylthyazole derivative | |
DK148479B (da) | Fremgangsmaade til fremstilling af 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxid | |
JPS61502959A (ja) | 4↓−(イソキサゾリル)↓−チアゾ−ル↓−2↓−オキサミド酸誘導体 | |
KR900005111B1 (ko) | 4-히드록시-3-(헤테로시클로카르바모일)-2h-1,2-벤조티아진-1,1-디옥시드의 제조 방법 | |
US4041042A (en) | Intermediate composition | |
CA1182824A (en) | P-oxooxazolidinylbenzene sulfonamides as antibacterial agents | |
HU201084B (en) | Basically substituted 5-halothienoisothiazol-3(2h)-one-1,1-dioxides, process for their preparation and pharmaceutical compositions containing them | |
US3978073A (en) | 3-(Chlorocetamido)-5-methyl isoxazole | |
JPS6223751B2 (da) | ||
CA1163631A (en) | Isoxazole derivatives and a process for the preparation thereof | |
JPS6035344B2 (ja) | チアゾリジン誘導体の製造方法 | |
JPH06211819A (ja) | ベンジリデン誘導体 | |
KR810000758B1 (ko) | 페닐 피페라진 유도체의 제조방법 | |
PT94904A (pt) | Processo para a preparacao de derivados benzotiazinicos e de composicoes farmaceuticas que os contem | |
US3575995A (en) | Amino isoxazoles | |
WO1995026959A1 (fr) | Derive alkylenediamine |